Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
Background:
Blood stem cells in the bone marrow make all the cells to normally defend a body against
disease. Allogeneic blood or marrow transplant is when these stem cells are transferred from
one person to another. Researchers think this treatment can provide a new, healthy immune
system to correct T-cell problems in some people.
Objective:
To see if allogeneic blood or bone marrow transplant is safe and effective in treating people
with T-cell problems.
Eligibility:
Donors: Healthy people ages 4 and older
Recipients: People the same age with abnormal T-cell function causing health problems
Design:
All participants will be screened with:
- Medical history
- Physical exam
- Blood, heart, and urine tests
Donors will also have an electrocardiogram and chest x-ray. They may have veins tested or a
pre-anesthesia test.
Recipients will also have lung tests.
Some participants will have scans and/or bone marrow collected by needle in the hip bones.
Donors will learn about medicines and activities to avoid and repeat some screening tests.
Some donors will stay in the hospital overnight and have bone marrow collected with
anesthesia.
Other donors will get shots for several days to stimulate cells. They will have blood removed
by plastic tube (IV) in an arm vein. A machine will remove stem cells and return the rest of
the blood to the other arm.
Recipients will have:
- More bone marrow and a small fragment of bone removed
- Dental, diet, and social worker consultations
- Scans
- Chemotherapy and antibody therapy for 2 weeks
- Catheter inserted in a chest or neck vein to receive donor stem cells
- A hospital stay for several weeks with more medicines and procedures
- Multiple follow-up visits